Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial-Reference-Cited by-同舟云学术

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

Published:2013-01 Issue:1 Volume:14 Page:72-80
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Mackey John R,Martin Miguel,Pienkowski Tadeusz,Rolski Janusz,Guastalla Jean-Paul,Sami Amer,Glaspy John,Juhos Eva,Wardley Andrew,Fornander Tommy,Hainsworth John,Coleman Robert,Modiano Manuel R,Vinholes Jeferson,Pinter Tamas,Rodríguez-Lescure Álvaro,Colwell Bruce,Whitlock Pierre,Provencher Louise,Laing Kara,Walde David,Price Chris,Hugh Judith C,Childs Barrett H,Bassi Kimberly,Lindsay Mary-Ann,Wilson Véronique,Rupin Matthieu,Houé Vincent,Vogel Charles

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials;De Laurentiis;J Clin Oncol,2008

2. Adjuvant docetaxel for node-positive breast cancer;Martin;N Engl J Med,2005

3. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

4. Gene expression patterns of breast cancinomas distinguished tumor subclasses with clinical implications;Sorlie;Proc Natl Acad Sci USA,2001

5. Common toxicity criteria manual, version 1.0,1982

Cited by 185 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis;European Journal of Cancer;2024-05

2. Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial;Breast Cancer: Targets and Therapy;2024-04

3. Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer;Nanoscale;2024

4. Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development;Interdisciplinary Cancer Research;2024

5. Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality;Journal of Clinical Oncology;2023-11-10